Lipopolysaccharide Is a Direct Agonist for Platelet RNA Splicing

Pavel N. Shashkin, G. Thomas Brown, Arundhati Ghosh, Gopal K. Marathe and Thomas M. McIntyre
J Immunol September 1, 2008, 181 (5) 3495-3502; DOI: https://doi.org/10.4049/jimmunol.181.5.3495

Abstract

Platelets express TLR4 receptors, but its ligand LPS does not directly activate thrombotic functions nor, obviously, transcription by these anucleate cells. Platelets, however, store information that changes their phenotype over a few hours in the form of unprocessed RNA transcripts. We show even low concentrations of LPS in the presence of soluble CD14 initiated splicing of unprocessed IL-1β RNA, with translation and accumulation of IL-1β protein. LPS was a more robust agonist for this response than thrombin. Platelets also contained cyclooxygenase-2 pre-mRNA, which also was spliced and translated after LPS stimulation. Flow cytometry and immunocytochemistry of platelets extensively purified by negative immunodepletion showed platelets contained IL-1β, and quantitative assessment of white blood cell contamination by CD14 real time PCR confirms that leukocytes were not the IL-1β source, nor were they required for platelet stimulation. LPS did not initiate rapid platelet responses, but over time did prime platelet aggregation to soluble agonists, induced actin rearrangement, and initiated granule secretion with P-selectin expression that resulted the coating of quiescent leukocytes with activated platelets. LPS is a direct agonist for platelets that allows these cells to directly participate in the innate immune response to bacteria.

Lipopolysaccharide stimulates gene transcription in nucleated inflammatory cells through its interaction with extracellular LPS-binding protein (LBP),3 the CD14 displayed on the cell surface, and the transmembrane signaling receptor TLR4 (1). Platelets express TLR4 (2, 3, 4) in sufficient quantities to physically bind LPS (5), but they do not express CD14. This need not exclude potential platelet responsiveness to LPS because plasma contains microgram levels of soluble CD14 (6) that also can present LPS to TLR4. In vivo experiments show that LPS promotes platelet function (2, 4, 7, 8), induces thrombocytopenia (4), and expands the inflammatory reaction through TNF-α expression (4). Whether these events result from a direct effect on platelets is debated because LPS neither enhances rapid homotypic platelet aggregation (7, 9, 10) nor induces surface P-selectin expression (2, 7, 10) by isolated platelets. LPS does enhance platelet adhesion to fibrinogen under flow (2), although it is less effective at this than thrombin, and it enhances surface expression of GPIIb/GPIIIa and CD40L through TLR4 (5). LPS, it is clear, is a poor agonist for typical ex vivo platelet responses, although this may reflect the type of LPS used because LPS from enterohemorrhagic Escherichia coli are potent platelet agonists (5).

Platelets lack nuclei and so cannot transcribe new mRNA to alter their proteome, but they do contain a select group of mRNAs (11, 12, 13, 14) that are translated to new protein in a highly regulated manner (11, 15, 16, 17). Platelets also contain unprocessed RNA transcripts, and they possess a functional, activation-dependent spliceosome that converts these transcripts to translatable mRNAs (18, 19, 20). One of these platelet pre-mRNA that is spliced and translated to new protein after thrombin stimulation encodes the multifaceted inflammatory cytokine IL-1β (18). Thrombin activated platelets move IL-1β to their surface (21, 22) where it participates in juxtacrine stimulation of endothelial cells (21), and they secrete small amounts of mature IL-1β (23) that participates in the inflammatory process. These observations have now been challenged with the suggestion that even low numbers of monocytes in platelet preparations are sufficient to account for thrombin-stimulated IL-1β production (24). Assessing contaminating nucleated cells in platelet preparations is difficult (25) when their abundance needs to be less than one per hundred thousand platelets (24). This is an important topic given that extreme leukoreduction, on the order of one leukocyte per million platelets, is a critical issue in platelet transfusion medicine (Ref. 26 , and references therein). Purifying platelets to this extent without activation is problematic, so these opposing views regarding the direct effects of LPS on platelets have yet to be reconciled.

Platelets express cyclooxygenase-1, which produces thromboxane A2 that enhances homotypic aggregation (27). Cyclooxygenase-1 is irreversibly inhibited by aspirin, while the cyclooxygenase-2 isoform, which can be induced by inflammatory stimuli in a variety of cells, is less sensitive to this inhibitor (28). Because this might contribute to the clinical and laboratory phenomenon of aspirin resistance (29), the presence of cyclooxygenase-2 in platelets has been well studied. Although cyclooxygenase-2 occasionally has been reported in platelets (30, 31), potentially remaining from megakaryopoiesis (32), it is not apparent that mature platelets express cyclooxygenase-2 (33, 34). Platelets stimulated over a short time by thrombin also do not express functional cyclooxygenase-2 (33).

Platelets have a role in inflammation beyond their initial, rapid response (18, 19, 20, 35), and in this study, we show that LPS is a potent agonist for prolonged platelet responses. We generated highly purified platelets by negative immunoselection and then quantified monocyte contamination by quantitative RT-PCR for CD14 mRNA. This allowed us to show that LPS acts directly on platelets to induce RNA processing and translation, including cyclooxygenase-2 RNA processing and expression, functionally altered platelet physiology, and initiated platelet coating of quiescent leukocytes.

Materials and Methods

Cell isolation

Human blood in a protocol approved by the Cleveland Clinic IRB was drawn into acid-citrate-dextrose and centrifuged (200 × g, 20 min) to obtain platelet-rich plasma. All centrifugations were without braking. Platelet-rich plasma was filtered through two layers of 5 μ mesh (BioDesign) to remove nucleated cells and recentrifuged (500 × g, 20 min) in the presence of 100 nM prostaglandin E1. The pellet was resuspended in 50 ml PIPES/saline/glucose (5 mM PIPES, 145 mM NaCl, 4 mM KCl, 50 μM Na2HPO4, 1 mM MgCl2, and 5.5 mM glucose) containing 100 nM of prostaglandin E1. These cells were centrifuged (500 × g, 20 min), resuspended in AutoMACS sample buffer, 5 μl anti-CD45-, anti-CD15-, anti-CD14 and anti-glycophorin-coated magnetic beads (Miltenyi Biotec) per 109 cells for 25 min with constant rotation before purification in an AutoMACS magnetic separator (Miltenyi Biotec). For some experiments, this negative microbead selection was repeated. Light microscopy was used to confirm the cells had a discoidal, unactivated shape. Recovered platelets were centrifuged (500 × g, 20 min) and resuspended in HBSS/A (0.5% human serum albumin in HBSS) at 4 × 108 cells/ml for confocal microscopy, aggregation and FACS analysis, and at 8 × 108 platelets/ml for all other uses. Platelet activation was induced by 100 ng/ml LPS or KDO2-Lipid A, 10 μg/ml Pam3Cys-SK4, or 0.1 U of thrombin for the stated time. Autologous serum (0.5%) or recombinant soluble CD14 and LBP (final concentration 0.15 μg/ml and 0.1 μg/ml, respectively) was added with TLR4 agonists. Density purified monocytes were isolated as before (36).

RNA isolation and real time RT-PCR

Total RNA from 2.4 × 109 platelets or 107 monocytes or PMN was isolated using RNEasy Mini Kit (Qiagen) and treated with RNase-free DNase (Qiagen). Total RNA was quantitated by NanoDrop and used to normalize PCR samples. Real time reverse transcriptase-PCR primers for: IL1β mRNA, sense 5′-AAACCTCTTCGAGGCACAAG-3′ (exon 1), antisense 5′-GTTTAGGGCCATCAGCTTCA-3′ (exon 3); COX-2 mRNA, sense 5′-TGAAACCCACTCCAAACACA-3′ (exon 3) and antisense 5′-GAGAAGGCTTCCCAGCTTTT-3′ (exon 4); CD14 mRNA, sense 5′-GGGTTCACAGAGGAGGGAAC-3′ (exon 1), antisense 5′-CGCGCTCCATGGTCGATA-3′ (the junction between exon 1 and 2). Conditions for IL-1β were: reverse transcription (50°C, 30′); PCR (94°C, 15″; 61°C, 30″; 72°C, 30″); data collection (80°C, 15″), 40–45 cycles with SYBR Green I in either an Applied Biosystems ABI Prism 7700 Sequence Detection System or a MyCycler. This amplification across intron 2 does not detect unprocessed IL-1β RNA. Conditions for COX-2 and CD14 were the same, with the exception that annealing temperature was 60°C and 61.9°C, respectively, and data collection for COX-2 was at 75.5°C. Products were analyzed by melting curve, gel electrophoresis, and sequencing. DNase I treatment did not affect IL-1β mRNA expression, while RNase I and no RT abolished amplification.

Confocal microscopy

Platelets were incubated for the stated times in gelatin-coated 4-well borosilicate chambered coverslips. Adherent cells were washed with endotoxin-free PBS and fixed with 2% paraformaldehyde for 30 min. Globular G-actin was detected using Alexa594-DNase I, and polymerized F-actin with Alexa488-phalloidin. IL-1β expression was visualized with anti-IL-1β Ab and Alexa488-conjugated goat-anti-mouse. Plasma membranes were stained with Alexa594-wheat germ agglutinin. White blood cell nuclei were stained with 4′,6′-diamidino-2-phenylindole (DAPI). Microscopy used a Plan Apochromat ×63, N.A.1.4 oil objective and processed with Leica confocal software.

Nucleation assay

Platelets were incubated in gelatin-coated 4-well borosilicate chambered coverslips as above. After 3 h of incubation, cells were permeabilized with saponin and challenged with 2 μM rhodamine G-actin for 5 min. Cells were then fixed with 2% paraformaldehyde, blocked by 10 min incubation in 0.1M glycine, washed five times in PBS, and counterstained with Alexa488-phalloidin. Samples were mounted in Vectashield (Vector Laboratories) and examined under epifluorescence. The intensity of G-actin staining was analyzed using Image-Pro software (Media Cybernetics).

Flow cytometry

FACScan analysis used the same anti-IL-1β as above and PerCP-conjugated secondary goat-anti-mouse Abs. Cells were washed and then permeabilized using BD Pharmingen Cytofix/Cytoperm kits. Platelets were gated by forward and side scatter that defined a CD42b+ population.

Aggregometry

Acid-citrate-dextrose initiated aggregation in platelet-rich plasma, assessed by transmittance (Chrono-Log). Platelets from different donors demonstrated broad variation in their agonist sensitivity, ranging from 2 to 10 μg/ml collagen (n = 13), so a threshold concentration was determined for every donor.

Western blotting and mass spectrometry

Monocytes or platelets were incubated with buffer or LPS and MG132, lysed in RIPA buffer, and the proteins were resolved by SDS-PAGE before the resulting blot was stained with anti-cycloxygenase-2 mAb and goat-anti-mouse-HRP tagged secondary Ab. Actin staining of a duplicate blot used mouse-anti-actin mAb followed by goat-anti-mouse-HRP tagged secondary Ab. The unique cyclooxygenase-2 peptide LILIGETIK was detected by mass spectrometry after the appropriate sized band was excised from a 1D SDS-PAGE, reduced, alkylated, and digested with trypsin. The digests were analyzed on an LTQ linear ion trap instrument (ThermoFinnigan) with selected reaction monitoring.

Chemicals and reagents

Chemicals and reagents were purchased from the following sources: sterile filtered HBSS and M199, BioWhittaker; sterile tissue culture plates, Falcon Labware; human serum albumin, Baxter Healthcare; endotoxin-free PBS, phenol-extracted LPS (Escherichia coli O111:B4) that is free of lipoprotein contamination, List Biological Laboratories; KDO2-Lipid A, Avanti Polar Lipids; Pam3Cys-SK4 and Cdc2-like kinase (Clk-1) inhibitor TG003, Calbiochem; 4-well Lab-Tek II Chamber Slide System, Nalge Nunc International; Alexa594 chicken anti-rabbit IgG (H+L), Alexa488-phalloidin, Alexa594-wheat germ agglutinin, Alexa594-DNase I, and DAPI, Molecular Probes; recombinant soluble CD14, LBP, IL-1β ELISA kit, ELISPOT kit, IL-1β Ab, R&D Systems; PerCP-conjugated goat-anti-mouse, FITC-mouse IgG1, PE-anti-human CD42b, and PE-mouse IgG1κ, BD Pharmingen; anti-cyclooxygenase-2 and cognate peptide, Cayman Chemical; rhodamine-labeled G-actin, Cytoskeleton. Other chemicals were from Sigma-Aldrich or Biomol Research Laboratories.

Expression of data and statistics

Experiments were performed at least three times with cells from different donors, and all assays were performed in triplicate. The mean ± SE from all experiments are presented. Representative experiments are shown in some cases because we observed significant interassay variation in IL-1β expression from different donors. ANOVA was used to determine differences among the groups. If significant differences were found, a Newman-Keuls post hoc procedure was used to determine the location of the difference. A value of p < 0.05 was considered statistically significant.

Results

LPS stimulates IL-1β transcript processing

Thrombin rapidly stimulates platelet processing of IL-1β pre-mRNA to functional, intronless mRNA (18), which we confirmed using real time PCR with primers anchored in exons 1 and 3 that do not amplify unprocessed message (Fig. 1⇓A). The progression curves of the real time PCR show that E. coli LPS also induced platelet IL-1β RNA processing, and was significantly better at this than thrombin. The thousand-fold increase in spliced IL-1β RNA after LPS exposure was time dependent (Fig. 1⇓B); maximal accumulation of processed IL-1β RNA occurred 3 h after stimulation, but with significant accumulation of spliced message 1 h after LPS exposure. Accumulation of processed IL-1β RNA in response to LPS developed more slowly than in response to the complete platelet agonist thrombin, but was both more effective and more prolonged (Fig. 1⇓B). The amount of processed RNA after stimulation with either agonist gradually declined, although not to background levels, by 20 h post stimulation. The loss of processed RNA was not due to a loss of cell viability or functionality because platelets, even after 20 h of continuous LPS stimulation, remained metabolically competent with functional, polarized mitochondria that could be depolarized with the protonophore CCCP (Fig. 1⇓C).

FIGURE 1.
FIGURE 1.

LPS induces IL-1β RNA processing in purified platelets. A, Real-time RT-PCR progression curves for spliced IL-1β RNA. Logarithmic accumulation of IL-1β amplicons using primers anchored in exons 1 and 3. Duplicate determinations using RNA extracted from platelets (8 ng total RNA) left untreated, or stimulated with 0.1 U thrombin for 30 min, or 100 ng/ml LPS along with 150 ng/ml recombinant CD14 and 100 ng/ml LPS-binding protein (LBP) for 3 h. ΔRn is the magnitude of the signal normalized to total RNA. B, Kinetics of IL-1β mRNA accumulation. The accumulation of spliced IL-1β RNA in purified human platelets treated with 0.1 U/ml thrombin or LPS in the presence of soluble CD14 and LBP (in three separate experiments ± SE) compared with the basal amount by quantitative RT-PCR as in the above panel. C, Platelets remain viable after prolonged stimulation. Accumulation of the cationic dye MitoTracker Red, with or without (left) subsequent dissipation of the mitochondrial transmembrane potential with CCCP, was imaged after 20 h of LPS exposure. D, LPS stimulation of platelet RNA splicing requires TLR4 receptor components. Purified platelets were stimulated with 100 ng/ml LPS, 100 ng/ml KDO2-Lipid A, 100 μg/ml Pam3Cys-SK4, or 0.1 U of thrombin before RNA isolated 3 h later. Some samples contained soluble CD14 and LBP, while the competitive TLR4 receptor antagonist Rhodobacter sphaeroides LPS (RS-LPS) was present in one sample as stated. Bars represent SEs. n = 4.

The response to E. coli LPS was receptor mediated because it was enhanced by a source of soluble CD14, which is needed to present LPS to TLR4, that we supplied as recombinant CD14 along with LBP (Fig. 1⇑D). Additionally, the response to LPS was blocked by the competitive TLR4 antagonist (37) Rhodobacter sphaeroides LPS (Fig. 1⇑D). The invariant lipid core of LPS was all that was required to stimulate platelet splicing because the homogeneous lipid ligand KDO2-lipid A that lacks the outer carbohydrate chain of LPS was a highly effective agonist. Platelets express (4) the TLR2 receptor for endotoxic bacterial lipoproteins (38), and we found (Fig. 1⇑D) that the synthetic TLR2 agonist Pam3Cys-SK4, which contains the bioactive lipid modification of Gram-negative and Gram-positive bacterial lipoproteins, stimulated IL-1β RNA splicing. This synthetic lipopeptide was less effective than LPS, being about as effective as thrombin.

LPS stimulates IL-1β protein accumulation in platelets

Newly synthesized IL-1β primarily remains cell-associated in purified preparations of platelets stimulated by thrombin (16). Because platelet preparations contain contaminating monocytes, we used flow cytometery to define the population(s) of cells that synthesized and accumulated IL-1β in response to LPS stimulation. We gated the platelet population by forward and side scatter and then for cells that stained for surface CD42b (data not shown). Staining this population for IL-1β after permeabilization revealed no staining beyond background levels in unstimulated cells, with an increase in IL-1β over time after LPS stimulation (Fig. 2⇓A). This occurred in a way that varied with the concentration of agonist, with as little as 10 ng of E. coli LPS increasing the content of immunoreactive IL-1β (Fig. 2⇓B).

FIGURE 2.
FIGURE 2.

LPS treatment induces IL1β expression. A, Platelet IL-1β accumulation is time dependent. Purified platelets were treated with 100 ng/ml E. coli LPS, recombinant CD14 and recombinant LBP for the stated times as in Fig. 1, permeabilized, and stained with either anti-IL-1β or an isotype matched control Ab and then analyzed by flow cytometry as described in Materials and Methods. Both nonimmune and anti-IL-1β Abs were used at time 0 to define background binding, the shaded area and the light gray trace, that were equivalent. The ordinate is the number of events normalized to the maximal number of counts, the abscissa is the fluorescent channel 1 bin. B, LPS concentration/response profile. Platelets were treated with the stated concentration of LPS, along with recombinant CD14 and LBP, for 1 h, and then assessed for IL-1β expression as above. Representative of four independent experiments.

Monocytes are not required in the platelet response to LPS

Monocytes may directly, or indirectly through cytokine production, contribute to platelet IL-1β accumulation, and quantification of small numbers of contaminating monocytes is problematic. We took advantage of the abundant expression of CD14 by monocytes and the paucity of this component of LPS signaling on platelets to establish a quantitative definition of monocyte contamination by real time PCR for CD14 mRNA. This mRNA was abundant in unstimulated monocytes (Fig. 3⇓A), but was present in platelet-rich plasma even after filtration through a 5 μm mesh. We immunodepleted monocytes with a combination of anti-CD14, anti-CD15, and anti-CD45 conjugated to magnetic beads, while a second immunodepletion after addition of additional beads further reduced the CD14 RNA content. Based on RNA content, we calculate that 106 filtered, immunodepleted, and doubly immunodepleted platelets could contain up to 17 ± 16, 7.4 ± 3.6, and 2.5 ± 0.9 monocytes, respectively.

FIGURE 3.
FIGURE 3.

Platelets are a direct target of LPS stimulation. A, Quantitative assessment of the effectiveness of platelet purification by immunodepletion of leukocytes. Platelet rich plasma (PRP) was purified using anti-CD14, -CD15, -CD45 and anti-glycophorin coated magnetic beads by passage once or twice over a Miltenyi AutoMACS column. RNA was extracted from the recovered cells and normalized for total RNA content before the content of CD14 RNA was quantitatively assessed in duplicate samples by real-time PCR as described in Materials and Methods. B, ELISPOT detection of IL-1β producing cells in a preparation of purified platelets. The top leftmost panel is a negative buffer control, 0.8 ng rIL-1β (top middle), and 20,000 density purified monocytes stimulated by LPS (top right). The right panel shows 107 platelets stimulated by 100 ng LPS for 17 h. C, Confocal microscopy of cells in a platelet preparation expressing IL-1β. Platelets suspended over gelatin-coated cover slips were treated with 100 ng/ml LPS for the stated times, permeabilized, and then stained with mouse anti-IL-1β and Alexa 488-conjugated anti-mouse Ab (green) and Alexa 594-conjugated wheat germ agglutinin (WGA) that stains plasma membrane sialated proteins and gangliosides (red). The fixative contained the nuclear stain DAPI to identify contaminating white blood cells (blue). Upper inset: Higher magnification (×3.7) shows IL-1β is localized as punctate intracytoplasmic inclusions at times shortly after LPS addition. Lower inset: 24 h of incubation in the absence of LPS reveals lower levels of IL-1β staining. Representative of three experiments.

Monocyte-depleted platelet preparations still produced IL-1β after LPS stimulation when analyzed by ELISPOT (Fig. 3⇑B), and the frequency of cells expressing IL-1β after LPS stimulation was significantly greater than the 25 ± 9 monocytes that could have been present in the well. We visualized the cells that contained IL-1β by confocal microscopy and used DAPI to stain any contaminating nucleated cells in the platelet preparation. Confocal microscopy showed that LPS increased the number and intensity of cells that stained for IL-1β protein (Fig. 3⇑C), which was maximal by 6 h and then declined modestly after 18 h of LPS exposure. DAPI labeling of cell nuclei showed the platelet preparation was depleted of nucleated cells, and that all of the newly generated IL-1β protein was associated with anucleate platelets. We also found (data not shown) that inhibition of transcription by actinomycin D suppressed monocyte production of IL-1β, but not that associated with anucleate platelets. These data show stimulation of monocyte cytokine production has no part in the platelet response to LPS.

LPS stimulates platelet cyclooxygenase-2 RNA splicing

Quiescent platelets are reported (33, 34) to contain no cyclooxygenase-2, but to test whether LPS-stimulated platelets might do so, we designed primers that hybridized within exon 3 of cyclooxygenase-2 and at the junction formed by the splicing of exons 3 and 4. Little processed cyclooxygenase-2 RNA was present in unstimulated platelets, but we found that purified platelets stimulated by either LPS or the homogenous endotoxin KDO2-Lipid A now contained spliced cyclooxygenase-2 RNA (Fig. 4⇓A). Amplification across exons 9 and 10 confirmed that LPS initiated cyclooxygenase-2 splicing (data not shown). The synthetic TLR2 agonist (Fig. 4⇓A) and thrombin (data not shown) also stimulated splicing, but again were not as effective as the TLR4 agonists. Two-color flow cytometery (Fig. 4⇓B) showed the platelets that accumulated IL-1β protein after LPS stimulation also accumulated cyclooxygenase-2 protein. Highly purified platelet preparations expressed immunoreactive cyclooxygenase-2 at the appropriate m.w. after 17 h of LPS treatment (Fig. 4⇓C). Staining of this band was abolished by the cognate peptide, and peptide sequencing of this band by mass spectrometry demonstrated unique cyclooxygenase-2 peptides (data not shown).

FIGURE 4.
FIGURE 4.

Platelets express cyclooxygenase-2 after LPS stimulation. A, Progression curve of real-time PCR for spliced cyclooxygenase-2 RNA. Purified platelets were stimulated with 100 ng E. coli LPS, 100 ng KDO2-Lipid A, 100 μg Pam3Cys-SK4, or left untreated. RNA was extracted and tested as in Fig. 3 using primers anchored exon 3 and the junction formed by splicing exons 3 and 4. B, Platelet expression of IL-1β and cyclooxygenase-2. Purified platelets were stimulated with 100 ng/ml E. coli LPS for 3 h or left untreated, permeabilized, fixed, and stained with a combination of mouse anti-IL-1β and PerCP-conjugated goat anti-mouse Ab followed by a directly conjugated FITC-anti-cyclooxygenase-2 Ab. The cells were subjected to flow cytometry, gated by forward and side scatter, and FITC and PerCP fluorescence was assessed in channels FL1 and FL3, respectively. This experiment has been replicated more than fifteen times, although the level of cyclooxygenase-2 expression varied among donors. C, Cyclooxygenase-2 immunoblot in extracts of purified platelets. Platelets or density-purified monocytes were treated with LPS, recombinant soluble CD14 and LPS binding protein as in the preceding panel for 17 h, while monocytes were treated with 100 ng/ml LPS alone for 17 h. Upper panel, anti-cyclooxygenase-2 Western blot. Middle panel, anti-cyclooxygenase-2 Western blot using Ab preincubated with its cognate peptide. Lower panel, β-actin Western blot.

LPS alters platelet physiology over time

LPS was not a typical platelet agonist, and did not induce rapid platelet shape change or aggregation (data not shown), as previously reported (10). However, both LPS and KDO2-Lipid A augmented ADP-induced aggregation in platelet rich plasma (Fig. 5⇓A). In contrast to splicing, the synthetic TLR2 agonist Pam3Cys-SK4 was not an agonist for this response. Changes in platelet physiology in response to LPS included a rearrangement of their cytoskeleton with an increase in F-actin at the expense of monomeric G-actin (Fig. 5⇓B). Direct quantification of actin nucleation in platelet lysates by incorporation of rhodamine-labeled G-actin showed 3 h of LPS treatment increased actin polymerization 3.8 ± 0.8-fold. Changes in platelet physical structure after LPS exposure was also reflected in the change in both forward and side scatter during flow cytometry (Fig. 5⇓C) reflecting changes in granularity and microparticle formation.

FIGURE 5.
FIGURE 5.

LPS primes platelet aggregation and alters platelet structure. A, LPS primes ADP-induced aggregation in platelet-rich plasma (PRP). LPS (100 ng), KDO2-Lipid A (100 ng), or Pam3Cys-SK4 (100 μg) was added to 1 ml of PRP and incubated for 1 h before addition to a stirred aggregometer cuvette. As shown by the arrow, 20 μM ADP was added and light transmittance was assessed over the subsequent 6 min. LPS did not induce aggregation without the addition of ADP (data not shown). B, Polymerized actin staining of adherent platelets. Confocal microscopy images of control (left) and platelets stimulated with 100 ng/ml E. coli LPS (right) in the presence of autologous serum or soluble CD14 and LPS binding protein for 3 h. Green staining is polymerized (F-actin) stained by FITC-phalloidin and red fluorescence is unpolymerized G-actin. The bar is 20 μm. Lower insets: ×2 magnified fields of respective images. Upper inset: pretreatment with cytochalasin B abrogated actin polymerization. C, LPS affects platelet structure. Platelets were treated or not with LPS for 3 h as in the preceding panel and then analyzed by flow cytometry for forward scatter (size) and side scatter (granularity). The area of the gate imposed on the dot blot stained for the platelet protein CD42b. This experiment has been repeated more than twenty times.

Surface expression of granule-stored proteins was increased after 3 h of LPS exposure. Flow cytometry showed that LPS increased expression of CD40L in some cells with the formation of a CD40L high population (Fig. 6⇓A). LPS also initiated a time-dependent increase in surface P-selection expression that was evident by 1 h of exposure encompassing most platelets, with one population becoming particularly bright (Fig. 6⇓B). Neutrophils constitutively express P-selectin glycoprotein ligand–1, which serves as a ligand for the P-selectin displayed by activated platelets. Platelets treated with LPS for 2.5 h to increase surface P-selectin readily associated with quiescent neutrophils (Fig. 6⇓C). Blockade of this ligand-receptor interaction with anti-P-selectin mAb suppressed platelet-induced neutrophil interaction (data not shown).

FIGURE 6.
FIGURE 6.

LPS induces degranulation and P-selectin expression that promotes neutrophil binding. A, CD40L surface expression. Platelets were stimulated by LPS, or not, for 3 h, fixed, and stained with either mouse anti-CD40L or an isotype-matched control Ab before the cells were analyzed by flow cytometry. MFI, mean fluorescence intensity. B, P-selectin surface expression. Platelets were treated with buffer or 100 ng/ml LPS for 1 or 2 h before fixation, Ab staining, and flow cytometry as before. The shadowed area shows unstained platelets, the thin line defines isotype control Ab staining, while the bold line shows P-selectin (CD62P) staining. C, LPS-stimulated platelets decorate quiescent neutrophils. Platelets were treated with buffer or LPS for 2.5 h as before, washed, and then suspended with quiescent autologous neutrophils for 10 min on gelatin-coated slides, fixed, and stained for P-selectin (green FITC fluorescence), plasma membrane by Alexa 594-conjugated wheat germ agglutinin (red), and nuclei with DAPI (blue). The images are representative of three experiments.

Discussion

These data show platelets are components of the innate immune system that recognize and then respond to endotoxin. Over time, LPS sensitized platelets to soluble agonists, altered the platelet cytoskeleton, altered platelet size and granularity, generated microparticles, promoted degranulation, induced surface expression of P-selectin and CD40L, and promoted leukocyte binding. LPS also proved to be a robust agonist of platelet RNA processing and translation that eclipsed thrombin as an agonist. This occurred in the virtual absence of contaminating monocytes, which we could document by quantifying CD14 mRNA. Therefore, while LPS is a slowly acting secondary agonist for many of the responses typical of platelets, it now becomes the most robust agonist that alters the platelet transcriptome and proteome.

Whether LPS directly affects platelet function has been controversial (9, 10), but in vivo experiments are definitive and show the TLR4 receptor of platelets has a role at least in the systemic response to endotoxin (2, 4, 5). A critical issue to be answered in experiments examining LPS as an ex vivo platelet agonist is the potential role of monocytes remaining in the preparation because monocytes abundantly produce IL-1β that might then be incorrectly ascribed to activated platelets (24). Moreover, it is possible that LPS acts solely on monocytes to produce an agonist that then acts on platelets. Quantification of contaminating leukocytes at less than one per hundred thousand platelets (24) is problematic by flow cytometry (25), and platelet-monocyte aggregates will be excluded from the analysis. We approached this issue by first creating a protocol that produced highly purified platelet populations and then devising a method to quantitatively assess monocytic cell content in this preparation. We filtered platelet-rich plasma through 5 μm mesh, and then negatively purified platelets by removing cells that expressed CD14, CD15, and CD45, along with anti-glycophorin to remove residual erythrocytes, by magnetic bead separation. Although we found this reduced leukocyte contamination, we also found that a second pass through the AutoMax column after addition of additional Abs and magnetic beads further reduced nucleated cell contamination, perhaps because the sample overloaded the capacity of the column.

Platelets are not known to express CD14 and, accordingly, we found it necessary to provide exogenous CD14, provided either as a recombinant protein or as the constitutively expressed protein in human serum (data not shown), to aid their response to LPS. This enhancement varied among donors, but most often the response was greatly enhanced by exogenous CD14. Platelets, then, are analogous to endothelial cells (39, 40) that are aided by circulating soluble CD14 and LBP. In contrast, CD14 is a prominent mRNA and protein of monocytes, and so quantifying CD14 mRNA by real time PCR provides a quantifiable measure of the number of monocytes that could be present in any given platelet preparation. We used this value to show that the number of cells expressing IL-1β in an ELISPOT assay was significantly larger than the maximum number of monocytes that could be present, and used this approach to show that an equivalent number of monocytes fail to produce detectable IL-1β (data not shown). We found that reducing the number of contaminating monocytes to a few per million platelets did not diminish the responsiveness of the platelet population to LPS, and, as a complementary direct test, we found that blocking transcription with actinomycin D blocked IL-1β production by purified monocytes but not purified platelets. All these data show that LPS is a direct platelet agonist.

LPS stimulation of platelets initiated splicing of cyclooxygenase-2 RNA and ultimately, production of the corresponding protein. This occurred in highly purified platelet populations and in a population of cells defined as platelets during flow cytometry by forward, scatter, side scatter, and CD42b staining. Western blotting and mass spectrometry confirmed the presence of the protein in LPS-stimulated platelets. We emphasize, however, the extreme variability of this response, even when compared with IL-1β expression; the protein was present in some preparations without activation, while in others it could not be up-regulated by LPS stimulation. The basis for this variability may lie in donor variability. More importantly, we could not demonstrate increased product formation nor sensitivity to the cyclooxygenase-2 inhibitor NS398 (data not shown). Unstimulated platelets are not a source of cyclooxygenase-2 products (34), and it appears LPS stimulated platelets either generate protein that is not active, or it is present in insufficient quantities to affect arachidonate metabolism.

These data show that LPS synergizes with rapidly acting stimuli, but over time develops an independent capacity as a direct platelet agonist. Platelets also express TLR1, TLR2, TLR6, and TLR9 (4, 41, 42), and a synthetic TLR2 ligand, the only other TLR ligand we tested, proved to be an agonist, although a weak one, for splicing. Agonist stimulation of platelet splicing and activation-dependent translation of platelet mRNA includes IL-1β (18), Bcl-3 that aids clot retraction (43), tissue factor (19), now cyclooxygenase-2, and indeed many other currently unidentified proteins (11). LPS promoted platelet granule release accompanied by surface P-selectin expression that then promoted leukocyte interaction, so in vivo endotoxin exposure has the potential to directly alter platelet reactivity. Indeed, in vivo exposure to LPS shows platelet TLR4 to be a critical component of the response to endotoxemia (2).

A key distinction between the findings reported in this study and other experiments examining the effect of LPS on platelets that requires emphasis is that LPS is not a typical rapidly acting, soluble agonist. Thus, the response of platelets to LPS developed over time and, for example, the binding of human neutrophils to LPS-stimulated platelets was apparent after several hours (Fig. 6⇑C) and not after several minutes (data not shown) of incubation. Platelet responses are typically analyzed as immediate responses to introduced agonists, and LPS modulation of platelet function does not fit the paradigm of established platelet agonists. The measured rate of change in platelet phenotype after LPS stimulation indicates that the effect of LPS on platelets will manifest in systemic changes, rather than local ones, as indeed has been observed in in vivo models of endotoxemia (2).

Acknowledgments

The technical aid of Mark Calabro, Manisha Sharma, Jessica Cemate, and Stacy Macecevic is greatly appreciated, as was the helpful advice of Drs. Andrew Weyrich and Guy Zimmerman. The experiment performed by R. Chen is greatly appreciated. The significant aid of Dr. Michael Kinter and the Mass Spectrometry core facility and the aid of Dr. Josephine Adams with the nucleation assay are gratefully acknowledged. We thank Dr. D. Zeldin (National Institutes of Health/NIEHS, Research Triangle Park, NC) for the gift of recombinant cyclooxygenase-1. Figure preparation by Diana Lim is, again, greatly appreciated. We appreciate the support provided by the Flow Cytometry and Imaging core laboratories of the Lerner Research Institute. We have no commercial conflicts.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by Grant P50 HL081011.

  • ↵2 Address correspondence and reprint requests to Dr. Thomas M. McIntyre, Department of Cell Biology, NE-10, Lerner Research Institute, Cleveland Clinic Lerner College of Medicine, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail address: mcintyt{at}ccf.org

  • ↵3 Abbreviations used in this paper: LBP, LPS-binding protein; DAPI, 4′,6′- diamidino-2-phenylindole.

  • Received March 7, 2008.
  • Accepted June 19, 2008.

References

  1. ↵
    Palsson-McDermott, E. M., L. A. O'Neill. 2004. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113: 153-162.
    OpenUrlCrossRefPubMed
  2. ↵
    Andonegui, G., S. M. Kerfoot, K. McNagny, K. V. Ebbert, K. D. Patel, P. Kubes. 2005. Platelets express functional Toll-like receptor-4. Blood 106: 2417-2423.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Cognasse, F., H. Hamzeh, P. Chavarin, S. Acquart, C. Genin, O. Garraud. 2005. Evidence of Toll-like receptor molecules on human platelets. Immunol. Cell Biol. 83: 196-198.
    OpenUrlCrossRefPubMed
  4. ↵
    Aslam, R., E. R. Speck, M. Kim, A. R. Crow, K. W. Bang, F. P. Nestel, H. Ni, A. H. Lazarus, J. Freedman, J. W. Semple. 2006. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 107: 637-641.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Stahl, A. L., M. Svensson, M. Morgelin, C. Svanborg, P. I. Tarr, J. C. Mooney, S. L. Watkins, R. Johnson, D. Karpman. 2006. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 108: 167-176.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Lodrup Carlsen, K. C., B. Granum. 2007. Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr. Allergy Asthma Rep. 7: 436-443.
    OpenUrlCrossRefPubMed
  7. ↵
    Rumbaut, R. E., R. V. Bellera, J. K. Randhawa, C. N. Shrimpton, S. K. Dasgupta, J. F. Dong, A. R. Burns. 2006. Endotoxin enhances microvascular thrombosis in mouse cremaster venules via a TLR4-dependent, neutrophil-independent mechanism. Am. J. Physiol. 290: H1671-H1679.
    OpenUrl
  8. ↵
    Clark, S. R., A. C. Ma, S. A. Tavener, B. McDonald, Z. Goodarzi, M. M. Kelly, K. D. Patel, S. Chakrabarti, E. McAvoy, G. D. Sinclair, et al 2007. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13: 463-469.
    OpenUrlCrossRefPubMed
  9. ↵
    Montrucchio, G., O. Bosco, L. Del Sorbo, P. Fascio Pecetto, E. Lupia, A. Goffi, P. Omede, G. Emanuelli, G. Camussi. 2003. Mechanisms of the priming effect of low doses of lipopolysaccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb. Haemostasis 90: 872-881.
    OpenUrlPubMed
  10. ↵
    Ward, J. R., L. Bingle, H. M. Judge, S. B. Brown, R. F. Storey, M. K. Whyte, S. K. Dower, D. J. Buttle, I. Sabroe. 2005. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb. Haemostasis 94: 831-838.
    OpenUrlPubMed
  11. ↵
    Weyrich, A. S., D. A. Dixon, R. Pabla, M. R. Elstad, T. M. McIntyre, S. M. Prescott, G. A. Zimmerman. 1998. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc. Natl. Acad. Sci. USA 95: 5556-5561.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Bahou, W. F., D. V. Gnatenko. 2004. Platelet transcriptome: the application of microarray analysis to platelets. Semin. Thromb. Hemostasis 30: 473-484.
    OpenUrlCrossRefPubMed
  13. ↵
    Macaulay, I. C., P. Carr, A. Gusnanto, W. H. Ouwehand, D. Fitzgerald, N. A. Watkins. 2005. Platelet genomics and proteomics in human health and disease. J. Clin. Invest. 115: 3370-3377.
    OpenUrlCrossRefPubMed
  14. ↵
    Dittrich, M., I. Birschmann, J. Pfrang, S. Herterich, A. Smolenski, U. Walter, T. Dandekar. 2006. Analysis of SAGE data in human platelets: features of the transcriptome in an anucleate cell. Thromb. Haemostasis 95: 643-651.
    OpenUrlPubMed
  15. ↵
    Pabla, R., A. S. Weyrich, D. A. Dixon, P. F. Bray, T. M. McIntyre, S. M. Prescott, G. A. Zimmerman. 1999. Integrin-dependent control of translation: engagement of integrin αIIbβ3 regulates synthesis of proteins in activated human platelets. J. Cell Biol. 144: 175-184.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Lindemann, S., N. D. Tolley, D. A. Dixon, T. M. McIntyre, S. M. Prescott, G. A. Zimmerman, A. S. Weyrich. 2001. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J. Cell Biol. 154: 485-490.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Lindemann, S., N. D. Tolley, J. R. Eyre, L. W. Kraiss, T. M. Mahoney, A. S. Weyrich. 2001. Integrins regulate the intracellular distribution of eukaryotic initiation factor 4e in platelets: a checkpoint for translational control. J. Biol. Chem. 276: 33947-33951.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Denis, M. M., N. D. Tolley, M. Bunting, H. Schwertz, H. Jiang, S. Lindemann, C. C. Yost, F. J. Rubner, K. H. Albertine, K. J. Swoboda, et al 2005. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122: 379-391.
    OpenUrlCrossRefPubMed
  19. ↵
    Schwertz, H., N. D. Tolley, J. M. Foulks, M. M. Denis, B. W. Risenmay, M. Buerke, R. E. Tilley, M. T. Rondina, E. M. Harris, L. W. Kraiss, et al 2006. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J. Exp. Med. 203: 2433-2440.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Panes, O., V. Matus, C. G. Saez, T. Quiroga, J. Pereira, D. Mezzano. 2007. Human platelets synthesize and express functional tissue factor. Blood 109: 5242-5250.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Hawrylowicz, C. M., G. L. Howells, M. Feldmann. 1991. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J. Exp. Med. 174: 785-790.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Hawrylowicz, C. M., S. A. Santoro, F. M. Platt, E. R. Unanue. 1989. Activated platelets express IL-1 activity. J. Immunol. 143: 4015-4018.
    OpenUrlAbstract
  23. ↵
    Loppnow, H., R. Bil, S. Hirt, U. Schonbeck, M. Herzberg, K. Werdan, E. T. Rietschel, E. Brandt, H. D. Flad. 1998. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 91: 134-141.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Pillitteri, D., S. Bassus, K. Boller, R. Mahnel, T. Scholz, D. Westrup, W. Wegert, C. M. Kirchmaier. 2007. Thrombin-induced interleukin 1β synthesis in platelet suspensions: impact of contaminating leukocytes. Platelets 18: 119-127.
    OpenUrlCrossRefPubMed
  25. ↵
    van der Meer, P. F., J. W. Gratama, C. J. van Delden, R. F. Laport, W. H. Levering, J. G. Schrijver, M. J. Tiekstra, M. Keeney, J. de Wildt-Eggen. 2001. Comparison of five platforms for enumeration of residual leucocytes in leucoreduced blood components. Br. J. Haematol. 115: 953-962.
    OpenUrlCrossRefPubMed
  26. ↵
    Semple, J. W., E. R. Speck, D. Cosgrave, A. H. Lazarus, V. S. Blanchette, J. Freedman. 1999. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood 93: 713-720.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Kinsella, B. T., D. O'Mahony, J. A. Lawson, D. Pratico, G. A. Fitzgerald. 1994. Cellular activation of thromboxane receptors. Ann. NY Acad. Sci. 714: 270-278.
    OpenUrlCrossRefPubMed
  28. ↵
    Simmons, D. L., R. M. Botting, T. Hla. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56: 387-437.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Patrono, C., B. Rocca. 2007. Drug insight: aspirin resistance: fact or fashion?. Nat. Clin. Pract. Cardiovasc. Med. 4: 42-50.
    OpenUrlCrossRefPubMed
  30. ↵
    Censarek, P., K. Freidel, M. Udelhoven, S. J. Ku, T. Hohlfeld, J. Meyer-Kirchrath, K. Schror, A. A. Weber. 2004. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb. Haemostasis 92: 925-928.
    OpenUrlPubMed
  31. ↵
    Weber, A. A., B. Przytulski, M. Schumacher, N. Zimmermann, E. Gams, T. Hohlfeld, K. Schror. 2002. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br. J. Haematol. 117: 424-426.
    OpenUrlCrossRefPubMed
  32. ↵
    Rocca, B., P. Secchiero, G. Ciabattoni, F. O. Ranelletti, L. Catani, L. Guidotti, E. Melloni, N. Maggiano, G. Zauli, C. Patrono. 2002. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc. Natl. Acad. Sci. USA 99: 7634-7639.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Patrignani, P., M. G. Sciulli, S. Manarini, G. Santini, C. Cerletti, V. Evangelista. 1999. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J. Physiol. Pharmacol. 50: 661-667.
    OpenUrlPubMed
  34. ↵
    Reiter, R., U. Resch, H. Sinzinger. 2001. Do human platelets express COX-2?. Prostaglandins Leukotrienes Essent. Fatty Acids 64: 299-305.
    OpenUrlCrossRefPubMed
  35. ↵
    Weyrich, A. S., S. Lindemann, N. D. Tolley, L. W. Kraiss, D. A. Dixon, T. M. Mahoney, S. P. Prescott, T. M. McIntyre, G. A. Zimmerman. 2004. Change in protein phenotype without a nucleus: translational control in platelets. Semin. Thromb. Hemostasis 30: 491-498.
    OpenUrlCrossRefPubMed
  36. ↵
    Weyrich, A. S., M. M. Denis, J. R. Kuhlmann-Eyre, E. D. Spencer, D. A. Dixon, G. K. Marathe, T. M. McIntyre, G. A. Zimmerman, S. M. Prescott. 2005. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 111: 633-642.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Lien, E., T. K. Means, H. Heine, A. Yoshimura, S. Kusumoto, K. Fukase, M. J. Fenton, M. Oikawa, N. Qureshi, B. Monks, et al 2000. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105: 497-504.
    OpenUrlCrossRefPubMed
  38. ↵
    Morr, M., O. Takeuchi, S. Akira, M. M. Simon, P. F. Muhlradt. 2002. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur. J. Immunol. 32: 3337-3347.
    OpenUrlCrossRefPubMed
  39. ↵
    Frey, E. A., D. S. Miller, T. G. Jahr, A. Sundan, V. Bazil, T. Espevik, B. B. Finlay, S. D. Wright. 1992. Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176: 1665-1671.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Pugin, J., C. C. Schurer-Maly, D. Leturcq, A. Moriarty, R. J. Ulevitch, P. S. Tobias. 1993. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 90: 2744-2748.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Semple, J. W., M. Coopamh, J. Freedman. 2004. Murine platelets express toll like receptor 2: A potential regulator of innate and adaptive immunity. Platelets 15: 267
    OpenUrl
  42. ↵
    Shiraki, R., N. Inoue, S. Kawasaki, A. Takei, M. Kadotani, Y. Ohnishi, J. Ejiri, S. Kobayashi, K. Hirata, S. Kawashima, M. Yokoyama. 2004. Expression of Toll-like receptors on human platelets. Thromb. Res. 113: 379-385.
    OpenUrlCrossRefPubMed
  43. ↵
    Weyrich, A. S., M. M. Denis, H. Schwertz, N. D. Tolley, J. Foulks, E. Spencer, L. W. Kraiss, K. H. Albertine, T. M. McIntyre, G. A. Zimmerman. 2006. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 109: 1975-1983.
    OpenUrlPubMed
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section